EGFR and non-small cell lung carcinoma: In patients with driver-gene positive NSCLC-BMs, such as those harboring epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement, new-generation targeting reagents have a favorable intracranial response rate (66%–78%) (5, 6).